Tag Directory / ELILILLY     showing 1–10 of 10


Eli Lilly's new program aims to boost employer coverage of GLP-1s / Endpoints

Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #weightloss #healthcarefinance

GLP-1 medication changes may support long-term weight management

15 hrs / medicalxpress

Wegovy may have highest 'eye stroke' and sight loss risk among semaglutide GLP-1 agonists

15 hrs / medicalxpress

2018 to 2025 saw rise in GLP-1 receptor agonist Rx for bariatric surgery-eligible patients

17 hrs / medicalxpress

Carrum Health teams up with Virta Health on a comprehensive weight loss solution

21 hrs / fiercehealthcare

Ascletis touts GLP-1 quarterly dosing data; Mineralys apnea Phase 2 misses

23 hrs / endpoints / ENDPOINTS

Mouse brain study reveals why blockbuster weight-loss drugs may work differently in females and males

33 hrs / medicalxpress

Digital nudges help GLP-1 users: Stanford

40 hrs / beckershospitalreview / Giles Bruce

Hims & Hers makes deal with Novo Nordisk as it shifts obesity strategy

44 hrs / fiercehealthcare

10 drugs poised to be global best-sellers in 2030

46 hrs / beckershospitalreview / Paige Twenter

AbbVie, Gubra post obesity data; Regeneron obesity drug succeeds in China

46 hrs / endpoints / ENDPOINTS

Amazon Pharmacy expands Zepbound access

47 hrs / beckershospitalreview / Ella Jeffries

Hims agrees to limit compounding, ending feud with Novo Nordisk

47 hrs / endpoints / Shelby Livingston

Novo, Hims strike GLP-1 deal after legal feud

2 days / beckershospitalreview / Ella Jeffries

Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete?

2 days / medcitynews / Frank Vinluan

Lilly Employer Connect Adds Flexibility for Employers But Isn’t Revolutionary, Expert Says

5 days / medcitynews / Marissa Plescia

Eli Lilly's new program aims to boost employer coverage of GLP-1s

5 days / endpoints / Shelby Livingston

Saturday, March 7, 2026, 10:21 pm / permalink 20341 / 16 stories in 3 days


GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people / Medical Express

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #drugdevelopment #behavioralhealth

AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis

4 days / medicalxpress

Drugs Behind the Ozempic Weight-Loss Boom May Also Lower the Risk of Addiction

4 days / discovermagazine

Some patients keep weight off with fewer GLP-1 injections, study finds

4 days / medicalxpress

How do GLP-1 agonists affect gene expression?

4 days / medicalxpress

Eric Topol: GLP-1 Drugs Reduce Substance Abuse Risk in Over 600,000 US Veterans

4 days / oncodaily

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

5 days / medicalxpress

GLP-1 drugs tied to lower addiction risk: Study

5 days / beckershospitalreview / Ella Jeffries

GLP‑1 drugs like Ozempic may lower the risk of addiction: New study

5 days / medicalxpress

Friday, March 6, 2026, 12:23 pm / permalink 20276 / 8 stories in 4 days


Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints

Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment

GoodRx Launches Employer Program to Help Subsidize High-Cost Brand Drugs

9 days / medcitynews / Marissa Plescia

GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more

11 days / endpoints / Nicole DeFeudis

Walgreens Introduces Virtual Weight Management Offering

11 days / medcitynews / Marissa Plescia

Walgreens debuts virtual weight management clinic with access to GLP-1 meds

11 days / fiercehealthcare

Understanding GLP-1 signaling: A path to better therapies

12 days / medicalxpress

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

12 days / endpoints / Elizabeth Cairns

Walgreens launches $49 virtual weight management visits

12 days / beckershospitalreview / Ella Jeffries

Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects

13 days / endpoints / Elizabeth Cairns

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial

13 days / medicalxpress

Annie Wong: Transforming Melanoma and Cancer Care Through the 2026 Lea Medal

15 days / oncodaily

Zepbound beats Novo Nordisk’s experimental GLP-1 in head-to-head trial

15 days / beckershospitalreview / Paige Twenter

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

16 days / endpoints / Elizabeth Cairns

Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 13 days


Lilly appeals retatrutide classification ruling in case that could impact compounders / Endpoints

Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...

#obesity #healthcare #pharmaceuticals #elililly #weightloss #publichealth #drugdevelopment #fda #digitalhealth

Eli Lilly tests GLP-1 psoriasis combo in phase 3 trial

18 days / beckershospitalreview / Ella Jeffries

Video: Using combined therapy to treat obesity

19 days / medicalxpress

What's next for GLP-1s?

19 days / medicalxpress

Weight-loss drug 'support supplements': Do they address nutrient deficiencies, or are they just another fad?

21 days / medicalxpress

Weight-loss wonder pills prompt scrutiny of their key ingredient

21 days / medicalxpress

Taking the next shot: GLP-1 research and the new era of weight loss

21 days / medicalxpress

Overweight, obesity remained highly prevalent in US youths in 2024

21 days / medicalxpress

Inside Health

22 days / bbc

Bariatric surgery programs face upheaval amid growing GLP-1 use for weight loss

22 days / medicalxpress

Drugs Behind Ozempic and Wegovy Are Being Repurposed — Here Are 5 Others

23 days / discovermagazine

Will Ozempic-style patches help you lose weight? Two experts explain

24 days / medicalxpress

Obesity rates are rising, despite GLP-1s. What does it mean?

24 days / medicalxpress

White-label telehealth provider, pharmacy sued over 'snake oil' compounded oral GLP-1

25 days / fiercehealthcare

Lilly appeals retatrutide classification ruling in case that could impact compounders

25 days / endpoints / Alexis Kramer

Lilly stockpiles $1.5B worth of weight loss pill ahead of US approval

26 days / endpoints / Anna Brown

Saturday, February 14, 2026, 12:21 pm / permalink 19191 / 15 stories in 24 days


Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Al-Ola Abdallah: Discussing Updates of CAR-T in Malignant Hematology with Nausheen Ahmed

20 days / oncodaily

J&J pours $1B into new cell therapy site in Pennsylvania

20 days / endpoints / Nicole DeFeudis

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

21 days / endpoints / Elizabeth Cairns

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

21 days / sciencedaily

Caroline Pothet: The 2026 Workplan of the Committee For Advanced Therapies is Available

22 days / oncodaily

Eddie Cliff: Why CAR T Infusion Timing Doesn’t Change Outcomes in LBCL

22 days / oncodaily

Optimizing CAR T-cell therapy to tackle solid tumors

22 days / medicalxpress

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B

29 days / medcitynews / Frank Vinluan

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

29 days / endpoints / Kyle LaHucik

Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days


Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech

Stephen Liu: What GLP-1 Therapies May Mean for Cancer Risk

7 wks / oncodaily

#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

7 wks / endpoints / Andrew Dunn

A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

7 wks / endpoints / Shelby Livingston

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

7 wks / beckershospitalreview / Ella Jeffries

Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 7 wks


NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

7 wks / oncodaily

Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory

1 month / endpoints / Andrew Dunn

Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 7 wks


FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #governmentpolicy #fda

Physician-Journalist Shines Light on Measles Upsurge and New GLP-1 Study

7 wks / kffhealthnews

What Merck’s Chief Medical Officer Thinks of Lilly’s Approach to GLP-1s

7 wks / medcitynews / Arundhati Parmar

Long-term GLP-1 use trims medical cost growth: Aon

7 wks / beckershospitalreview / Elizabeth Casolo

GLP-1s tied to improved survival in colorectal cancer

7 wks / beckershospitalreview / Paige Twenter

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

7 wks / medicalxpress

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

7 wks / nature / Atul Malhotra

FDA moves to strike suicide risk warnings from 3 GLP-1s

7 wks / beckershospitalreview / Ella Jeffries

FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels

1 month / endpoints / Zachary Brennan

Thursday, January 15, 2026, 1:23 pm / permalink 17924 / 8 stories in 7 wks


Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily

oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]

#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment

How to watch one of the year's best meteor showers, the Geminids

3 months / go

Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025

3 months / oncodaily

Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 2 months


What Trump’s New Drug Pricing Deal Means for People With Obesity / NYT

Rebecca Robbins, Dani Blum and Margot Sanger-Katz / nytimes - The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

#trumpadministration #obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #governmentpolicy

Pfizer triumphs over Novo Nordisk with $10B bid for Metsera

4 months / endpoints / Elizabeth Cairns

Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

4 months / nytimes / Francesca Regalado

White House strikes new deals to lower prices on obesity drugs for some

4 months / npr / Sydney Lupkin

Trump Announces Deal to Drop Obesity Drug Prices to as Little as $149 a Month

4 months / nytimes / Rebecca Robbins, Margot Sanger-Katz and Dani Blum

What Trump’s New Drug Pricing Deal Means for People With Obesity

4 months / nytimes / Rebecca Robbins, Dani Blum and Margot Sanger-Katz

Eli Lilly, Novo Nordisk strike deals with White House to cut prices of weight loss drugs

4 months / fiercehealthcare

Friday, November 7, 2025, 11:57 pm / permalink 15780 / 6 stories in 4 months


Back to Top


ELILILLY Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.